by Elena Iemma | Jan 12, 2026 | Blog, News
In 2025, EpiVax advanced the science of immunogenicity assessment through AI-driven ADA prediction, enhanced in silico tools, expanded in vitro assays and consulting offerings, and new regulatory frameworks supporting biologics and generic peptides. Advancing...
by Elena Iemma | Jul 17, 2025 | Blog
Tregs, Epitopes, and the Future of Immune Tolerance Making Sense of Natural Constraint Contrary to popular (immunologist) belief, there’s nothing ‘non-specific’ about Tregs! Otherwise why would they carry TCR (T cell receptors) that bind to their...
by Elena Iemma | Apr 30, 2025 | Events
The 11th annual Amsterdam Immunogenicity & Tolerance Seminar November 7, 2025 | 8:30 am – 4:00 pm with reception to follow | The Hilton Apollolaan Hotel Registration is now closed About the Amsterdam Immunogenicity & Tolerance Seminar: Now in its 11th...
by Elena Iemma | Apr 30, 2025 | Events
The 17th annual Westin Immunogenicity Seminar Thursday, September 25, 2025 | 9:00 am – 6:00 pm | The Westin Hotel, Meguro, Tokyo Registration is closed Join us for the 17th Annual Westin Immunogenicity Seminar, a free event bringing together leaders in...
by Elena Iemma | Dec 23, 2023 | Blog
FDA Request for “Integrated Summary of Immunogenicity” So much news to share! EpiVax Delivers! As promised, EpiVax 2.0 will be arriving in 2024, our 26th year, along with new team members and new plans to expand the range of services offered. Here...
